CHARACTERIZATION OF PROSTATE-CANCER, BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATES USING TRANSRECTAL P-31 MAGNETIC-RESONANCE SPECTROSCOPY - A PRELIMINARY-REPORT

被引:41
作者
NARAYAN, P
JAJODIA, P
KURHANEWICZ, J
THOMAS, A
MACDONALD, J
HUBESCH, B
HEDGCOCK, M
ANDERSON, CM
JAMES, TL
TANAGHO, EA
WEINER, M
机构
[1] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT RADIOL,SAN FRANCISCO,CA 94143
[3] VET ADM MED CTR,SAN FRANCISCO,CA 94121
关键词
PROSTATE; CARCINOMA; PROSTATIC HYPERTROPHY; NUCLEAR MAGNETIC RESONANCE; PROSTATIC NEOPLASMS;
D O I
10.1016/S0022-5347(17)37716-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
We assessed the ability of phosphorus-31 (P-31) transrectal magnetic resonance spectroscopy to characterize normal human prostates as well as prostates with benign and malignant neoplasms. With a transrectal probe that we devised for surface coil spectroscopy we studied 15 individuals with normal (5), benign hyperplastic (4) and malignant (6) prostates. Digital rectal examination, transrectal ultrasonography and magnetic resonance imaging were used to aid in accurate positioning of the transrectal probe against the region of interest within the prostate. The major findings of the in vivo studies were that normal prostates had phosphocreatine-to-adenosine triphosphate (ATP) ratios of 1.2 +/- 0.2, phosphomonoester-to-beta-ATP ratios of 1.1 +/- 0.1 and phosphomonoester-to-phosphocreatine ratios of 0.9 +/- 0.1. Malignant prostates had phosphocreatine-to-beta-ATP ratios that were lower (0.7 +/- 0.1) than those of normal prostates (p < 0.02) or prostates with benign hyperplasia (1.1 +/- 0.2, p < 0.01). Malignant prostates had phosphomonoester-to-beta-ATP ratios (1.8 +/- 0.2) that were higher than that of normal prostates (p < 0.02). Using the phosphomonoester-to-phosphocreatine ratio, it was possible to differentiate metabolically malignant (2.7 +/- 0.3) from normal prostates (p < 0.001), with no overlap of individual ratios. The mean phosphomonoester-to-phosphocreatine ratio (1.5 +/- 0.5) of prostates with benign hyperplasia was midway between the normal and malignant ratios, and there was overlap between individual phosphomonoester-to-phosphocreatine ratios of benign prostatic hyperplasia glands with that of normal and malignant glands. To verify the in vivo results, we performed high resolution magnetic resonance spectroscopy on perchloric acid extracts of benign prostatic hyperplasia tissue obtained at operation and on a human prostatic cancer cell line DU145. The extract results confirmed the differences in metabolite ratios observed in vivo. We conclude that transrectal P-31 magnetic resonance spectroscopy can character metabolic differences between the normal and malignant prostate.
引用
收藏
页码:66 / 74
页数:9
相关论文
共 57 条
  • [1] BARANY M, 1984, PHOSPHORUS 31 NMR, P512
  • [2] THE CELL-CYCLE
    BASERGA, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (08) : 453 - 459
  • [3] BENDALL MR, 1983, J MAGN RESON, V53, P365, DOI 10.1016/0022-2364(83)90211-1
  • [4] BOTTOMLEY PA, 1989, RADIOLOGY, V170, P1
  • [5] ASSESSMENT OF TESTICULAR METABOLIC INTEGRITY WITH P-31 MR SPECTROSCOPY
    BRETAN, PN
    VIGNERON, DB
    HRICAK, H
    MCCLURE, RD
    YEN, TSB
    MOSELEY, M
    TANAGHO, EA
    JAMES, TL
    [J]. RADIOLOGY, 1987, 162 (03) : 867 - 871
  • [6] NMR SCANNING OF THE PELVIS - INITIAL EXPERIENCE WITH A 0.3 T SYSTEM
    BRYAN, PJ
    BUTLER, HE
    LIPUMA, JP
    HAAGA, JR
    ELYOUSEF, SJ
    RESNICK, MI
    COHEN, AM
    MALVIYA, VK
    NELSON, AD
    CLAMPITT, M
    ALFIDI, RJ
    COHEN, J
    MORRISON, SC
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1983, 141 (06) : 1111 - 1118
  • [7] BURT CT, 1984, BIOMEDICAL MAGNETIC, P231
  • [8] COHEN JS, 1986, CANCER RES, V46, P4087
  • [10] CORBETT RJT, 1987, CANCER RES, V47, P5065